Solis Minerals Secures Cinto tenements, Peru
- Cynata Therapeutics (CYP) reveals an independent data safety monitoring board (DSMB) completes its review of the company’s diabetic foot ulcer (DFU) trial
- Following the review, the DSMB recommended that the clinical trial continue as planned
- Chief Medical Officer Dr Jolanta Airey said the positive recommendation is a key milestone which enables the company to continue patient enrolment as planned and complete the trial as soon as possible
- According to the company, undertaking a review by an independent DSMB is consistent with good clinical practice
- Shares in the company are up 5.88 per cent to close at 36 cents
